The [new test]( identifies biomarkers in a person’s blood that can objectively measure their current severity and future risk for [schizophrenia] and match them to treatments that will be most effective for their individual biology.
They identified biomarkers that were predictive of high hallucinations and high delusion states, as well as future psychiatric hospitalizations related to hallucinations and delusions. They also studied which biomarkers are targets of existing drugs, which enables the matching of patients to the right treatments.
use of this biomarker test can help reduce subjectivity and uncertainty from psychiatric assessments